Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding. |
Clinical Added Value
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
GG1c509S6nEAUnZX
